Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Xenon Pharmaceuticals Inc has a consensus price target of $56 based on the ratings of 16 analysts. The high is $65 issued by Cantor Fitzgerald on August 9, 2024. The low is $46 issued by SVB Leerink on August 11, 2022. The 3 most-recent analyst ratings were released by RBC Capital, Needham, and Cantor Fitzgerald on September 3, 2024, August 12, 2024, and August 9, 2024, respectively. With an average price target of $60 between RBC Capital, Needham, and Cantor Fitzgerald, there's an implied 47.09% upside for Xenon Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Xenon Pharmaceuticals (NASDAQ:XENE) was reported by RBC Capital on September 3, 2024. The analyst firm set a price target for $55.00 expecting XENE to rise to within 12 months (a possible 34.84% upside). 21 analyst firms have reported ratings in the last year.
The latest analyst rating for Xenon Pharmaceuticals (NASDAQ:XENE) was provided by RBC Capital, and Xenon Pharmaceuticals reiterated their outperform rating.
There is no last upgrade for Xenon Pharmaceuticals
There is no last downgrade for Xenon Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on September 3, 2024 so you should expect the next rating to be made available sometime around September 3, 2025.
While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a reiterated with a price target of $55.00 to $55.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $40.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.